199 related articles for article (PubMed ID: 21036211)
1. Choroidal neovascularization in pathologic myopia.
Dave V; Narayanan R
Am J Ophthalmol; 2010 Nov; 150(5):752; author reply 752-3. PubMed ID: 21036211
[No Abstract] [Full Text] [Related]
2. Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab.
Laud K; Spaide RF; Freund KB; Slakter J; Klancnik JM
Retina; 2006 Oct; 26(8):960-3. PubMed ID: 17031300
[No Abstract] [Full Text] [Related]
3. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab--a randomized controlled trial.
Gharbiya M; Giustolisi R; Allievi F; Fantozzi N; Mazzeo L; Scavella V; Gabrieli CB
Am J Ophthalmol; 2010 Mar; 149(3):458-64.e1. PubMed ID: 20172072
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia.
Tewari A; Dhalla MS; Apte RS
Retina; 2006; 26(9):1093-4. PubMed ID: 17151505
[No Abstract] [Full Text] [Related]
5. Myopic choroidal neovascularization.
Ruiz-Moreno JM; López-Gálvez MI; Donate J; Gomez-Ulla F; García-Arumí J; García-Layana A; Sellés I; Reche J; Montero JA; Pazos B; Zapata MA; Pastor JC
Ophthalmology; 2011 Dec; 118(12):2521-3. PubMed ID: 22136676
[No Abstract] [Full Text] [Related]
6. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia.
Hernández-Rojas ML; Quiroz-Mercado H; Dalma-Weiszhausz J; Fromow-Guerra J; Amaya-Espinosa A; Solís-Vivanco A; Reyna-Castelán E; Abraham-Marín M; Martínez-Castellanos MA; Aiello LP
Retina; 2007; 27(6):707-12. PubMed ID: 17621179
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
Chan WM; Lai TY; Liu DT; Lam DS
Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
[TBL] [Abstract][Full Text] [Related]
8. Ranibizumab treatment for choroidal neovascularization from causes other than age-related macular degeneration and pathological myopia.
Carneiro AM; Silva RM; Veludo MJ; Barbosa A; Ruiz-Moreno JM; Falcão MS; Brandão EM; Falcão-Reis FM
Ophthalmologica; 2011; 225(2):81-8. PubMed ID: 20881442
[TBL] [Abstract][Full Text] [Related]
9. Angiographic changes after bevacizumab.
Ikuno Y; Soga K; Wakabayashi T; Gomi F
Ophthalmology; 2009 Nov; 116(11):2263.e1. PubMed ID: 19883861
[No Abstract] [Full Text] [Related]
10. The effect of treatments given to patients before initiation of anti-vascular endothelial growth factor treatment.
Hedaya J; Freeman WR
Retina; 2008 Jun; 28(6):911-2; author reply 912. PubMed ID: 18536615
[No Abstract] [Full Text] [Related]
11. Intravitreal bevacizumab for peripapillary classic subretinal neovascularization.
Spandau UH; Jonas JB
Acta Ophthalmol Scand; 2007 May; 85(3):340-1. PubMed ID: 17488467
[No Abstract] [Full Text] [Related]
12. The use of intravitreal bevacizumab to treat choroidal neovascular membranes (CNVMs).
Derriman L; Marshall J; Moorman C; Downes SM
Retina; 2008 Jun; 28(6):910; author reply 910-1. PubMed ID: 18536613
[No Abstract] [Full Text] [Related]
13. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results.
Ikuno Y; Sayanagi K; Soga K; Sawa M; Tsujikawa M; Gomi F; Tano Y
Am J Ophthalmol; 2009 Jan; 147(1):94-100.e1. PubMed ID: 18774550
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results.
Gharbiya M; Allievi F; Mazzeo L; Gabrieli CB
Am J Ophthalmol; 2009 Jan; 147(1):84-93.e1. PubMed ID: 18774547
[TBL] [Abstract][Full Text] [Related]
15. Avastin in myopic choroidal neovascularisation: is age the limit?
Wong D; Li KK
Br J Ophthalmol; 2008 Aug; 92(8):1011-2. PubMed ID: 18653589
[No Abstract] [Full Text] [Related]
16. Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia.
Lalloum F; Souied EH; Bastuji-Garin S; Puche N; Querques G; Glacet-Bernard A; Coscas G; Soubrane G; Leveziel N
Retina; 2010 Mar; 30(3):399-406. PubMed ID: 20038864
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia.
Sakaguchi H; Ikuno Y; Gomi F; Kamei M; Sawa M; Tsujikawa M; Oshima Y; Kusaka S; Tano Y
Br J Ophthalmol; 2007 Feb; 91(2):161-5. PubMed ID: 16914470
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
[TBL] [Abstract][Full Text] [Related]
19. Comparing ranibizumab with bevacizumab.
Biswas P; Sengupta S; Choudhary R; Home S; Paul A; Sinha S
Ophthalmology; 2011 Mar; 118(3):600-600.e2. PubMed ID: 21376243
[No Abstract] [Full Text] [Related]
20. Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration.
Bom Aggio F; Eid Farah M; Melo GB
Acta Ophthalmol Scand; 2006 Oct; 84(5):713-4. PubMed ID: 16965511
[No Abstract] [Full Text] [Related]
[Next] [New Search]
